Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

NCT05383482 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
NSCLC
Cervical Cancer
Endometrial Cancer
Esophageal Cancer
Gastric and Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Afuresertib
DRUG: Nab paclitaxel
DRUG: Docetaxel
DRUG: Sintilimab

Sponsor

Laekna Limited